Viewing Study NCT03966118


Ignite Creation Date: 2025-12-25 @ 5:04 AM
Ignite Modification Date: 2025-12-26 @ 4:06 AM
Study NCT ID: NCT03966118
Status: UNKNOWN
Last Update Posted: 2019-06-03
First Post: 2019-02-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Sponsor: P. C. Thuss-Patience
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module